These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 5770131)

  • 21. Hyperuricemia and locomotor activity in developing rats.
    Barrera CM; Hunter RE; Dunlap WP
    Pharmacol Biochem Behav; 1989 Jun; 33(2):367-9. PubMed ID: 2813475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The defect of uric acid metabolism in Eck-fistula rats.
    Lauterburg B; Sautter V; Herz R; Colombo JP; Roch-Ramel F; Bircher J
    J Lab Clin Med; 1977 Jul; 90(1):92-100. PubMed ID: 17644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nicotinic acid inhibition of uricase.
    Fitzpatrick DA; FitzGerald O; McGeeney KF
    Ir J Med Sci; 1969 Nov; 8(11):531-4. PubMed ID: 4244313
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacological effects of 1,3,5-triazines and their excretion characteristics in the rat.
    Hropot M; Sörgel F; von Kerékjártó B; Lang HJ; Muschaweck R
    Adv Exp Med Biol; 1980; 122A():269-76. PubMed ID: 6893515
    [No Abstract]   [Full Text] [Related]  

  • 25. [A problem on the uric acid value of rats for clinical evaluation].
    Emori T; Nagase S
    Jikken Dobutsu; 1984 Jul; 33(3):357-60. PubMed ID: 6499936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of hyperuricemia with rasburicase review.
    de Bont JM; Pieters R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.
    Wu X; Wakamiya M; Vaishnav S; Geske R; Montgomery C; Jones P; Bradley A; Caskey CT
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):742-6. PubMed ID: 8290593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
    Terkeltaub R; Bushinsky DA; Becker MA
    Arthritis Res Ther; 2006; 8 Suppl 1(Suppl 1):S4. PubMed ID: 16820043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary excretion of uric acid, allantoin, and 8-OH-Deoxyguanosine in uricase-knockout mice.
    Inazawa K; Yamaguchi S; Hosoyamada M; Fukuuchi T; Tomioka NH; Yamaoka N; Kaneko K
    Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):559-565. PubMed ID: 27906613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A possible role for glass bead immobilized enzymes as therapeutic agents (immobilized uricase as enzyme therapy for hyperuricemia).
    Venter JC; Venter BR; Dixon JE; Kaplan NO
    Biochem Med; 1975 Jan; 12(1):79-91. PubMed ID: 806289
    [No Abstract]   [Full Text] [Related]  

  • 31. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
    Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
    J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allantoxanamide-induced myocardial necrosis in Sprague-Dawley vs spontaneously hypertensive rats.
    Wexler BC
    Proc Soc Exp Biol Med; 1982 Sep; 170(4):476-85. PubMed ID: 7122477
    [No Abstract]   [Full Text] [Related]  

  • 33. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
    Bomalaski JS; Clark MA
    Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Blood uric acid levels as an indicator of the response to physical loads].
    Krasnova AF; Samodanova GI; Usik SV; Iakovlev NN
    Fiziol Zh SSSR Im I M Sechenova; 1978 Apr; 64(4):538-42. PubMed ID: 658523
    [No Abstract]   [Full Text] [Related]  

  • 35. Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice.
    Wang Y; Zhu JX; Kong LD; Yang C; Cheng CH; Zhang X
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):232-7. PubMed ID: 15125693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia.
    Cai L; Li Q; Deng Y; Liu X; Du W; Jiang X
    Int J Mol Med; 2020 May; 45(5):1488-1500. PubMed ID: 32323736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis).
    Tang DH; Ye YS; Wang CY; Li ZL; Zheng H; Ma KL
    Exp Anim; 2017 Aug; 66(3):209-216. PubMed ID: 28302963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
    Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
    Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel xanthine dehydrogenase inhibitor (BOF-4272).
    Sato S; Tatsumi K; Nishino T
    Adv Exp Med Biol; 1991; 309A():135-8. PubMed ID: 1789192
    [No Abstract]   [Full Text] [Related]  

  • 40. Handling of allantoin by the rat kidney. Clearance and micropuncture data.
    Greger R; Lang F; Deetjen P
    Pflugers Arch; 1975 Jun; 357(3-4):201-7. PubMed ID: 1238985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.